Marshall Financial Group LLC Has $541,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Marshall Financial Group LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 53.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 6,285 shares of the company’s stock after selling 7,228 shares during the quarter. Marshall Financial Group LLC’s holdings in Novo Nordisk A/S were worth $541,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Natixis Advisors LLC increased its holdings in Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC grew its position in shares of Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after buying an additional 19,870 shares during the last quarter. Versant Capital Management Inc acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $86,000. Talbot Financial LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter worth approximately $4,066,000. Finally, Zions Bancorporation N.A. lifted its stake in shares of Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after acquiring an additional 6,726 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $87.94 on Friday. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a market cap of $394.65 billion, a PE ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45. The stock has a 50-day moving average of $95.35 and a 200-day moving average of $115.17. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Wall Street Analyst Weigh In

Several research analysts have issued reports on NVO shares. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.